LULU Stock Analysis: Lululemon Athletica | NASDAQ
Apparel Retail | NASDAQ, USA | Market Cap: 10.726m USD | 12M Return: -39.2% | US5500211090 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 600M
EPS Trend: -2.0%
Qual. Beats: 1
Rev. Trend: 96.0%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Lululemon Athletica Inc. (NASDAQ: LULU), founded in 1998 and headquartered in Vancouver, Canada, designs, distributes, and retails technical athletic apparel, footwear, and accessories under the lululemon brand. The company sells directly to consumers across the United States, Canada, Mexico, China, Hong Kong, Taiwan, Macau, and Greece, with additional international reach. Its product range includes pants, shorts, tops, and jackets designed for activities such as yoga, running, and training, alongside fitness-inspired accessories.
The company operates an omnichannel distribution model that combines company-operated stores, seasonal and pop-up locations, university campus retailers, yoga and fitness studios, outlet locations, a re-commerce program called Like New, and a direct-to-consumer e-commerce website. This mix of physical retail and digital channels is characteristic of premium apparel brands seeking to control brand experience and capture full margin across the customer journey.
Lululemon is classified within the Consumer Discretionary sector under the Apparel, Accessories & Luxury Goods sub-industry in the GICS framework. It went public on July 27, 2007, and is structured as a large-cap Canadian-listed equity.
- China revenue growth accelerates with new store openings
- US comparable sales weaken as discretionary spending cools
- Mens and international expansion drives double-digit revenue growth
| Net Income: 1.42b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 0.44 > 1.0 |
| NWC/Revenue: 19.33% < 20% (prev 18.08%; Δ 1.25% < -1%) |
| CFO/TA 0.23 > 3% & CFO 1.98b > Net Income 1.42b |
| Net Debt (751.4m) to EBITDA (2.56b): 0.29 < 3 |
| Current Ratio: 2.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.9m) vs 12m ago -5.65% < -2% |
| Gross Margin: 56.11% > 18% (prev 59.10%; Δ -2.99% > 0.5%) |
| Asset Turnover: 138.6% > 50% (prev 144.9%; Δ -6.33% > 0%) |
| Interest Coverage Ratio: 171.4 > 6 (EBIT TTM 2.02b / Interest Expense TTM 11.8m) |
| A: 0.25 (Total Current Assets 3.95b - Total Current Liabilities 1.80b) / Total Assets 8.48b |
| B: 0.51 (Retained Earnings 4.36b / Total Assets 8.48b) |
| C: 0.25 (EBIT TTM 2.02b / Avg Total Assets 8.00b) |
| D: 1.30 (Book Value of Equity 4.79b / Total Liabilities 3.69b) |
| Altman-Z'' = 6.39 = AAA |
| DSRI: 0.36 (Receivables 171.2m/462.5m, Revenue 11.1b/10.9b) |
| GMI: 1.05 (GM 59.10% / 56.11%) |
| AQI: 1.02 (AQ_t 0.06 / AQ_t-1 0.06) |
| SGI: 1.02 (Revenue 11.1b / 10.9b) |
| TATA: -0.07 (NI 1.42b - CFO 1.98b) / TA 8.48b) |
| Beneish M = -3.48 (Cap -4..+1) = AA |
As of September 18, 2026, the stock is trading at USD 99.39 with a total of 6,514,550 shares traded. Over the past week, the price has changed by +2.59%, over one month by -14.13%, over three months by -11.07% and over the past year by -39.20%.
Current recommended Stop Loss: 93.20 (which is 6.2% or 1.2 ATR below the current price).
Lululemon Athletica has received a consensus analysts rating of 3.83. Therefore, it is recommended to buy LULU.
- StrongBuy: 16
- Buy: 3
- Hold: 14
- Sell: 1
- StrongSell: 2
| Analysts Target Price | 107.4 | 8.1% |
P/E Trailing = 8.2102
P/E Forward = 9.5329
P/S = 0.9668
P/B = 2.3042
P/EG = 1.0035
Revenue TTM = 11.1b USD
EBIT TTM = 2.02b USD
EBITDA TTM = 2.56b USD
Long Term Debt = 1.77b USD (estimated: total debt 2.14b - short term 366.6m)
Short Term Debt = 366.6m USD (from shortTermDebt, last quarter)
Debt = 2.14b USD (from shortLongTermDebtTotal, last quarter) (leases 2.14b already included)
Net Debt = 751.4m USD (calculated: Debt 2.14b - CCE 1.39b)
Enterprise Value = 11.5b USD (10.7b + Debt 2.14b - CCE 1.39b)
Interest Coverage Ratio = 171.4 (Ebit TTM 2.02b / Interest Expense TTM 11.8m)
EV/FCF = 8.47x (Enterprise Value 11.5b / FCF TTM 1.35b)
FCF Yield = 11.80% (FCF TTM 1.35b / Enterprise Value 11.5b)
FCF Margin = 12.21% (FCF TTM 1.35b / Revenue TTM 11.1b)
Net Margin = 12.78% (Net Income TTM 1.42b / Revenue TTM 11.1b)
Gross Margin = 56.11% ((Revenue TTM 11.1b - Cost of Revenue TTM 4.87b) / Revenue TTM)
Gross Margin QoQ = 60.52% (prev 54.17%)
Tobins Q-Ratio = 1.35 (Enterprise Value 11.5b / Total Assets 8.48b)
Interest Expense / Debt = 0.55% (Interest Expense 11.8m / Debt 2.14b)
Taxrate = 29.40% (590.5m / 2.01b)
NOPAT = 1.43b (EBIT 2.02b * (1 - 29.40%))
Current Ratio = 2.19 (Total Current Assets 3.95b / Total Current Liabilities 1.80b)
Debt / Equity = 0.45 (Debt 2.14b / totalStockholderEquity, last quarter 4.79b)
Debt / EBITDA = 0.29 (Net Debt 751.4m / EBITDA 2.56b)
Debt / FCF = 0.55 (Net Debt 751.4m / FCF TTM 1.35b)
Total Stockholder Equity = 4.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.72% (Net Income 1.42b / Total Assets 8.48b)
RoE = 29.73% (Net Income TTM 1.42b / Total Stockholder Equity 4.77b)
RoCE = 30.87% (EBIT 2.02b / Capital Employed (Equity 4.77b + L.T.Debt 1.77b))
RoIC = 21.96% (NOPAT 1.43b / Invested Capital 6.49b)
WACC = 8.17% (E(10.7b)/V(12.9b) * Re(9.72%) + D(2.14b)/V(12.9b) * Rd(0.55%) * (1-Tc(0.29)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.55 | Cagr: -4.87%
[DCF] Terminal Value 77.97% ; FCFF base≈1.28b ; Y1≈1.47b ; Y5≈2.16b
[DCF] Fair Price = 300.6 (EV 32.5b - Net Debt 751.4m = Equity 31.7b / Shares 105.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -1.99 | EPS CAGR: -0.19% | SUE: 2.11 | # QB: 1
Revenue Correlation: 95.96 | Revenue CAGR: 7.30% | SUE: -1.04 | # QB: -1
EPS current Quarter (2026-10-31): EPS=1.02 | Chg30d=-59.42% | Revisions=-22% | Analysts=15
EPS current Year (2027-01-31): EPS=9.61 | Chg30d=-12.92% | Revisions=-22% | GrowthEPS=-27.5% | GrowthRev=-5.8%
EPS next Year (2028-01-31): EPS=9.05 | Chg30d=-21.07% | Revisions=-22% | GrowthEPS=-5.9% | GrowthRev=+0.3%
[Analyst] Revisions Ratio: -29% (up=6, down=12)